Home › Companies › Palvella Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Palvella Therapeutics, Inc.’s Form 8-K, filed June 16, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 10, 2026: 7 items on Palvella Therapeutics, Inc.’s Form 8-K, filed June 16, 2026: 3 approved · 4 passed (calculated).
Notable dissent: 1 director (18.2% against); 2 other board items (24.8%, 24.3% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2025-2026
Explore Palvella Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Palvella Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 16, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: George M. Jenkins | 9,907,220 | -- | -- | 268,834 | 1,401,415 | 97% | Passed (calculated) | — |
| Elect Director: Todd C. Davis | 8,321,303 | -- | -- | 1,854,751 | 1,401,415 | 82% | Passed (calculated) | — |
| Elect Director: John Doux, M.D. | 9,958,528 | -- | -- | 217,526 | 1,401,415 | 98% | Passed (calculated) | — |
| 2. Ratification of Independent Registered Public Accountant | 11,557,687 | 13,216 | 6,566 | -- | -- | 99.9% | Approved | — |
| 3. Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2025 | 10,008,180 | 160,717 | 7,157 | -- | 1,401,415 | 98% | Approved | — |
| 5. Approval of an amendment to the Palvella Therapeutics, Inc | 7,692,709 | 2,475,470 | 7,875 | -- | 1,401,415 | 76% | Approved | — |
| 6. Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5 | 7,649,243 | 2,519,068 | 7,743 | -- | 1,401,415 | 75% | Passed (calculated) | — |
Source: Palvella Therapeutics, Inc., Form 8-K, filed with the SEC on June 16, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
195 asset managers disclosed a vote on at least one Palvella Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Palvella Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of three director nominees to serve as Class III directors whose term will expire in 2029: George M. Jenkins
Palvella Therapeutics, Inc.’s own tally for this item (“Elect Director: George M. Jenkins”): 9,907,220 for, 268,834 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 61 asset managers below reported 2,899,920 for, 113,110 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 562,168 | 0 | 0 | 422 | For |
| Federated Hermes | 408,215 | 0 | 0 | 0 | For |
| T. Rowe Price | 306,933 | 0 | 0 | 0 | For |
| State Street | 292,935 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 231,484 | 0 | 0 | 0 | For |
| BlackRock | 194,278 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 163,475 | 0 | 0 | 0 | For |
| AllianceBernstein | 137,145 | 0 | 0 | 0 | For |
| Prudential/PGIM | 109,205 | 0 | 0 | 0 | For |
| Principal | 31,961 | 0 | 0 | 39,911 | Mixed |
| RBB FUND, INC. | 0 | 0 | 0 | 65,909 | Withhold |
| Legg Mason | 56,480 | 0 | 0 | 0 | For |
| Fidelity | 44,945 | 0 | 0 | 0 | For |
| Calamos | 33,071 | 0 | 0 | 0 | For |
| Royce | 31,500 | 0 | 0 | 0 | For |
| Neuberger Berman | 24,153 | 0 | 0 | 0 | For |
| Invesco | 23,629 | 0 | 0 | 0 | For |
| Charles Schwab | 22,955 | 0 | 0 | 0 | For |
| Jackson National | 20,757 | 0 | 0 | 0 | For |
| TIAA | 19,664 | 0 | 0 | 0 | For |
| Equitable | 19,564 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 15,353 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 12,371 | 0 | 0 | 0 | For |
| Victory Capital | 11,403 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 11,132 | 0 | 0 | 0 | For |
Showing the 25 largest of 61 asset managers. All 61 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of three director nominees to serve as Class III directors whose term will expire in 2029: John Doux, M.D.
Palvella Therapeutics, Inc.’s own tally for this item (“Elect Director: John Doux, M.D.”): 9,958,528 for, 217,526 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 61 asset managers below reported 2,901,140 for, 111,890 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 562,590 | 0 | 0 | 0 | For |
| Federated Hermes | 408,215 | 0 | 0 | 0 | For |
| T. Rowe Price | 306,933 | 0 | 0 | 0 | For |
| State Street | 292,935 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 231,484 | 0 | 0 | 0 | For |
| BlackRock | 194,278 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 163,475 | 0 | 0 | 0 | For |
| AllianceBernstein | 137,145 | 0 | 0 | 0 | For |
| Prudential/PGIM | 109,205 | 0 | 0 | 0 | For |
| Principal | 31,961 | 0 | 0 | 39,911 | Mixed |
| RBB FUND, INC. | 0 | 0 | 0 | 65,909 | Withhold |
| Legg Mason | 56,480 | 0 | 0 | 0 | For |
| Fidelity | 44,945 | 0 | 0 | 0 | For |
| Calamos | 33,071 | 0 | 0 | 0 | For |
| Royce | 31,500 | 0 | 0 | 0 | For |
| Neuberger Berman | 24,153 | 0 | 0 | 0 | For |
| Invesco | 23,629 | 0 | 0 | 0 | For |
| Charles Schwab | 22,955 | 0 | 0 | 0 | For |
| Jackson National | 20,757 | 0 | 0 | 0 | For |
| TIAA | 19,664 | 0 | 0 | 0 | For |
| Equitable | 19,564 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 15,353 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 12,371 | 0 | 0 | 0 | For |
| Victory Capital | 11,403 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 11,132 | 0 | 0 | 0 | For |
Showing the 25 largest of 61 asset managers. All 61 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: Election of three director nominees to serve as Class III directors whose term will expire in 2029: Todd C. Davis
Palvella Therapeutics, Inc.’s own tally for this item (“Elect Director: Todd C. Davis”): 8,321,303 for, 1,854,751 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 61 asset managers below reported 1,826,990 for, 1,186,036 withheld, 4 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 562,164 | 0 | 4 | 422 | For |
| Federated Hermes | 0 | 0 | 0 | 408,215 | Withhold |
| T. Rowe Price | 306,933 | 0 | 0 | 0 | For |
| State Street | 600 | 0 | 0 | 292,335 | Withhold |
| MUTUAL FUND SERIES TRUST | 231,484 | 0 | 0 | 0 | For |
| BlackRock | 194,278 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 163,475 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 137,145 | Withhold |
| Prudential/PGIM | 109,205 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 71,872 | Withhold |
| RBB FUND, INC. | 0 | 0 | 0 | 65,909 | Withhold |
| Legg Mason | 56,480 | 0 | 0 | 0 | For |
| Fidelity | 17,832 | 0 | 0 | 27,113 | Mixed |
| Calamos | 33,071 | 0 | 0 | 0 | For |
| Royce | 0 | 0 | 0 | 31,500 | Withhold |
| Neuberger Berman | 0 | 0 | 0 | 24,153 | Withhold |
| Invesco | 23,629 | 0 | 0 | 0 | For |
| Charles Schwab | 22,955 | 0 | 0 | 0 | For |
| Jackson National | 20,757 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 19,664 | Withhold |
| Equitable | 14,704 | 0 | 0 | 4,860 | Mixed |
| CARILLON SERIES TRUST | 0 | 0 | 0 | 15,353 | Withhold |
| Advisors' Inner Circle Fund III | 12,371 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 11,403 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 11,132 | Withhold |
Showing the 25 largest of 61 asset managers. All 61 are in the interactive database (link above).
75% Majority: yes · of votes cast
Description as filed by funds: APPROVAL OF AN ADJOURNMENT OF THE ANNUAL MEETING TO THE EXTENT THERE ARE INSUFFICIENT VOTES AT THE ANNUAL MEETING TO APPROVE PROPOSAL 5.
Palvella Therapeutics, Inc.’s own tally for this item (“6. Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5”): 7,649,243 for, 2,519,068 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 1,571,298 for, 1,434,082 against, 6,070 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 92,451 | 470,139 | 0 | 0 | Mixed |
| Federated Hermes | 408,215 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 306,933 | 0 | 0 | Against |
| State Street | 600 | 292,335 | 0 | 0 | Against |
| MUTUAL FUND SERIES TRUST | 231,484 | 0 | 0 | 0 | For |
| BlackRock | 194,278 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 163,475 | 0 | 0 | 0 | For |
| AllianceBernstein | 137,145 | 0 | 0 | 0 | For |
| Prudential/PGIM | 109,205 | 0 | 0 | 0 | For |
| Principal | 71,364 | 508 | 0 | 0 | For |
| RBB FUND, INC. | 65,909 | 0 | 0 | 0 | For |
| Legg Mason | 0 | 56,480 | 0 | 0 | Against |
| Fidelity | 4,406 | 40,539 | 0 | 0 | Mixed |
| Calamos | 33,071 | 0 | 0 | 0 | For |
| Royce | 0 | 31,500 | 0 | 0 | Against |
| Neuberger Berman | 0 | 24,153 | 0 | 0 | Against |
| Invesco | 23,629 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 22,955 | 0 | 0 | Against |
| Jackson National | 0 | 20,757 | 0 | 0 | Against |
| TIAA | 0 | 19,664 | 0 | 0 | Against |
| Equitable | 17,289 | 2,275 | 0 | 0 | Mixed |
| CARILLON SERIES TRUST | 0 | 15,353 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 7,011 | 5,360 | 0 | 0 | Mixed |
| Victory Capital | 0 | 11,403 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 11,132 | 0 | 0 | Against |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
66% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: APPROVAL OF AN AMENDMENT TO THE 2024 EQUITY INCENTIVE PLAN TO INCREASE THE AUTHORIZED SHARES ISSUABLE UNDER THE 2024 PLAN BY 750,000 SHARES.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 91,586 | 471,004 | 0 | 0 | Mixed |
| Federated Hermes | 408,215 | 0 | 0 | 0 | For |
| T. Rowe Price | 306,933 | 0 | 0 | 0 | For |
| State Street | 132 | 292,803 | 0 | 0 | Against |
| MUTUAL FUND SERIES TRUST | 231,484 | 0 | 0 | 0 | For |
| BlackRock | 194,278 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 163,475 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 137,145 | 0 | 0 | Against |
| Prudential/PGIM | 109,205 | 0 | 0 | 0 | For |
| Principal | 39,911 | 31,961 | 0 | 0 | Mixed |
| RBB FUND, INC. | 65,909 | 0 | 0 | 0 | For |
| Legg Mason | 0 | 56,480 | 0 | 0 | Against |
| Fidelity | 4,406 | 40,539 | 0 | 0 | Mixed |
| Calamos | 33,071 | 0 | 0 | 0 | For |
| Royce | 0 | 31,500 | 0 | 0 | Against |
| Neuberger Berman | 0 | 24,153 | 0 | 0 | Against |
| Invesco | 0 | 23,629 | 0 | 0 | Against |
| Charles Schwab | 0 | 22,955 | 0 | 0 | Against |
| Jackson National | 0 | 20,757 | 0 | 0 | Against |
| TIAA | 19,664 | 0 | 0 | 0 | For |
| Equitable | 14,704 | 4,860 | 0 | 0 | Mixed |
| CARILLON SERIES TRUST | 0 | 15,353 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 0 | 12,371 | 0 | 0 | Against |
| Victory Capital | 0 | 11,403 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 11,132 | 0 | 0 | Against |
Fund voting reports, all 60 managers: 1,706,735 for, 1,298,644 against, 6,070 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| First Light Asset Management, LLC | 750,908 | 0 | 0 | 0 | For |
| APIS CAPITAL ADVISORS, LLC | 50,000 | 0 | 0 | 0 | For |
| Vident Advisory, LLC | 0 | 153 | 0 | 0 | Against |
Institutional-manager reports, all 3 managers: 800,908 for, 153 against.
Combines 5 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.
Palvella Therapeutics, Inc.’s own tally for this item (“3. Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2025”): 10,008,180 for, 160,717 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers in 2025, as follows:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 562,590 | 0 | 0 | 0 | For |
| Federated Hermes | 408,215 | 0 | 0 | 0 | For |
| T. Rowe Price | 306,933 | 0 | 0 | 0 | For |
| State Street | 292,818 | 117 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 231,484 | 0 | 0 | 0 | For |
| BlackRock | 194,278 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 163,475 | 0 | 0 | 0 | For |
| AllianceBernstein | 137,145 | 0 | 0 | 0 | For |
| Prudential/PGIM | 109,205 | 0 | 0 | 0 | For |
| Principal | 71,872 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 65,909 | 0 | 0 | 0 | For |
| Legg Mason | 56,480 | 0 | 0 | 0 | For |
| Fidelity | 44,945 | 0 | 0 | 0 | For |
| Calamos | 33,071 | 0 | 0 | 0 | For |
| Royce | 31,500 | 0 | 0 | 0 | For |
| Neuberger Berman | 24,153 | 0 | 0 | 0 | For |
| Invesco | 0 | 23,629 | 0 | 0 | Against |
| Charles Schwab | 22,955 | 0 | 0 | 0 | For |
| Jackson National | 20,757 | 0 | 0 | 0 | For |
| TIAA | 19,664 | 0 | 0 | 0 | For |
| Equitable | 19,564 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 15,353 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 12,371 | 0 | 0 | 0 | For |
| Victory Capital | 11,403 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 11,132 | 0 | 0 | 0 | For |
Fund voting reports, all 61 managers: 2,956,351 for, 50,608 against, 6,070 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | 1,173,366 | 0 | 0 | 0 | For |
| BVF INC/IL | 960,989 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 882,400 | 0 | 0 | 0 | For |
| First Light Asset Management, LLC | 750,908 | 0 | 0 | 0 | For |
| State Street | 407,630 | 1,939 | 0 | 0 | For |
| Federated Hermes | 408,215 | 0 | 0 | 0 | For |
| T. Rowe Price | 388,383 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 275,465 | 712 | 0 | 0 | For |
| Siren, L.L.C. | 247,192 | 0 | 0 | 0 | For |
| AllianceBernstein | 228,820 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 195,230 | 0 | 0 | 0 | For |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 156,367 | 5,681 | 0 | 0 | For |
| Woodline Partners LP | 148,216 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 123,643 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 117,806 | 0 | 0 | 0 | For |
| Artisan | 102,703 | 0 | 0 | 0 | For |
| BlackRock | 98,433 | 421 | 0 | 0 | For |
| EMERALD ADVISERS, LLC | 87,399 | 0 | 0 | 0 | For |
| Aberdeen | 81,081 | 0 | 0 | 0 | For |
| Vanguard | 80,013 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 59,345 | 0 | 0 | 0 | For |
| Neuberger Berman | 52,580 | 0 | 0 | 0 | For |
| APIS CAPITAL ADVISORS, LLC | 50,000 | 0 | 0 | 0 | For |
| Avidity Partners Management LP | 49,275 | 0 | 0 | 0 | For |
| EMERALD MUTUAL FUND ADVISERS TRUST | 39,911 | 0 | 0 | 0 | For |
Institutional-manager reports, all 150 managers: 7,728,872 for, 111,301 against, 68 abstained, 1,385 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.9% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE PREFERRED FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Federated Hermes | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| MUTUAL FUND SERIES TRUST | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| PRIMECAP Odyssey Funds | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| Prudential/PGIM | 0 | 0 | 0 | 0 | -- |
| Principal | 0 | 0 | 0 | 0 | -- |
| RBB FUND, INC. | 0 | 0 | 0 | 0 | -- |
| Legg Mason | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Calamos | 0 | 0 | 0 | 0 | -- |
| Royce | 0 | 0 | 0 | 0 | -- |
| Neuberger Berman | 0 | 0 | 0 | 0 | -- |
| Invesco | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Jackson National | 0 | 0 | 0 | 0 | -- |
| TIAA | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| CARILLON SERIES TRUST | 0 | 0 | 0 | 0 | -- |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 0 | -- |
| Victory Capital | 0 | 0 | 0 | 0 | -- |
| ALPS ETF Trust | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 60 managers: 15,008 for, 6,070 abstained, 2,990,133 1 year, 218 3 year, 21 unknown. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | 0 | 0 | 0 | 0 | -- |
| BVF INC/IL | 0 | 0 | 0 | 0 | -- |
| Frazier Life Sciences Management, L.P. | 882,400 | 0 | 0 | 0 | For |
| First Light Asset Management, LLC | 750,908 | 0 | 0 | 0 | For |
| State Street | 0 | 0 | 0 | 0 | -- |
| Federated Hermes | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| JENNISON ASSOCIATES LLC | 0 | 0 | 0 | 0 | -- |
| Siren, L.L.C. | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| PRIMECAP MANAGEMENT CO/CA/ | 0 | 0 | 0 | 0 | -- |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 0 | 0 | 0 | 0 | -- |
| Woodline Partners LP | 0 | 0 | 0 | 0 | -- |
| ORBIMED ADVISORS LLC | 0 | 0 | 0 | 0 | -- |
| MPM BioImpact LLC | 0 | 0 | 0 | 0 | -- |
| Artisan | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| EMERALD ADVISERS, LLC | 0 | 0 | 0 | 0 | -- |
| Aberdeen | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Clearbridge Investments, LLC | 0 | 0 | 0 | 0 | -- |
| Neuberger Berman | 0 | 0 | 0 | 0 | -- |
| APIS CAPITAL ADVISORS, LLC | 50,000 | 0 | 0 | 0 | For |
| Avidity Partners Management LP | 0 | 0 | 0 | 0 | -- |
| EMERALD MUTUAL FUND ADVISERS TRUST | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 145 managers: 1,684,983 for, 35 against, 6,116,064 1 year, 39,288 3 year. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Approved · of votes cast
Prior year: 99.9% for (June 10, 2025 meeting) unchanged
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE 2026 FISCAL YEAR.
Palvella Therapeutics, Inc.’s own tally for this item (“2. Ratification of Independent Registered Public Accountant”): 11,557,687 for, 13,216 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The appointment of Ernst &Young LLP as the Company's independent registered public accounting firm for the 2026 fiscal year was ratified, as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 3,005,368 for, 12 against, 6,070 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 562,590 | 0 | 0 | 0 | For |
| Federated Hermes | 408,215 | 0 | 0 | 0 | For |
| T. Rowe Price | 306,933 | 0 | 0 | 0 | For |
| State Street | 292,923 | 12 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 231,484 | 0 | 0 | 0 | For |
| BlackRock | 194,278 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 163,475 | 0 | 0 | 0 | For |
| AllianceBernstein | 137,145 | 0 | 0 | 0 | For |
| Prudential/PGIM | 109,205 | 0 | 0 | 0 | For |
| Principal | 71,872 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 65,909 | 0 | 0 | 0 | For |
| Legg Mason | 56,480 | 0 | 0 | 0 | For |
| Fidelity | 44,945 | 0 | 0 | 0 | For |
| Calamos | 33,071 | 0 | 0 | 0 | For |
| Royce | 31,500 | 0 | 0 | 0 | For |
| Neuberger Berman | 24,153 | 0 | 0 | 0 | For |
| Invesco | 23,629 | 0 | 0 | 0 | For |
| Charles Schwab | 22,955 | 0 | 0 | 0 | For |
| Jackson National | 20,757 | 0 | 0 | 0 | For |
| TIAA | 19,664 | 0 | 0 | 0 | For |
| Equitable | 19,564 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 15,353 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 12,371 | 0 | 0 | 0 | For |
| Victory Capital | 11,403 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 11,132 | 0 | 0 | 0 | For |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 14,313,659 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.93% |
| 2 | Federated Hermes | 2.85% |
| 3 | T. Rowe Price | 2.14% |
| 4 | State Street | 2.05% |
| 5 | MUTUAL FUND SERIES TRUST | 1.62% |
| 6 | BlackRock | 1.36% |
| 7 | PRIMECAP Odyssey Funds | 1.14% |
| 8 | AllianceBernstein | 0.96% |
| 9 | Prudential/PGIM | 0.76% |
| 10 | Principal | 0.50% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | MONTANOVA CAPITAL, LLC | 8.20% |
| 2 | BVF INC/IL | 6.71% |
| 3 | Frazier Life Sciences Management, L.P. | 6.16% |
| 4 | First Light Asset Management, LLC | 5.25% |
| 5 | State Street | 2.86% |
| 6 | Federated Hermes | 2.85% |
| 7 | T. Rowe Price | 2.71% |
| 8 | JENNISON ASSOCIATES LLC | 1.93% |
| 9 | Siren, L.L.C. | 1.73% |
| 10 | AllianceBernstein | 1.60% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Wesley H. Kaupinen | 1,128,685 | 7.89% | Proxy statement (DEF 14A), table as of April 13, 2026 |
| PRUDENTIAL FINANCIAL INC | 962,374 | 6.72% | Schedule 13G, filed August 10, 2026 |
| Jennison Associates LLC | 960,619 | 6.71% | Schedule 13G, filed August 3, 2026 |
| Entities affiliated with First Light Asset Management, LLC | 887,031 | 6.20% | Proxy statement (DEF 14A), table as of April 13, 2026 |
| Entities affiliated with Biotechnology Value Fund, L.P. | 879,009 | 6.14% | Proxy statement (DEF 14A), table as of April 13, 2026 |
| Entities affiliated with Suvretta Capital Management, LLC | 822,400 | 5.75% | Proxy statement (DEF 14A), table as of April 13, 2026 |
| Entities affiliated with Frazier Life Sciences Public Fund, L.P. | 722,400 | 5.05% | Proxy statement (DEF 14A), table as of April 13, 2026 |
| Frazier Life Sciences Public Fund, L.P. | 706,360 | 4.93% | Schedule 13G, filed February 13, 2026 |
| BlackRock | 686,853 | 4.80% | Form 13F, quarter ended March 31, 2026 |
| BVF PARTNERS L P/IL | 672,789 | 4.70% | Schedule 13G, filed August 14, 2026 |
Percentages above are of 14,313,659 shares outstanding, as reported by Palvella Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Palvella Therapeutics, Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 195 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,843 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. — Palvella Therapeutics, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Palvella Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 16, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Palvella Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Palvella Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).
Proxy Votes Now, “Palvella Therapeutics (PVLA) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/palvella-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.